Although statins are widely used as cholesterol-lowering drugs, a recent study suggests that these compounds have anabolic effects on bone and could be developed into new treatments for common metabolic bone diseases such as osteoporosis
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Mundy, G. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946– 1949 (1999).
Alberts, A.W. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 77, 3957–3961 ( 1980).
Hamelin, B.A. & Turgeon, J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors . Trends Pharmacol. Sci. 19, 26– 37 (1998).
Zhang, F.L. & Casey, P.J. Protein prenylation: molecular mechanisms and functional consequences. Ann. Rev. Biochem. 65, 241–269 (1996).
Garrett, I.R., Escobedo, A. & Mundy, G.R. N2-containing bisphosphonates risedronate and ibandronate stimulate bone formation in organ culture. J. Bone Miner. Res. 14 S525 (abstract) (1999).
Luckman, S.P. et al. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13, 58 –589 (1998).
Fisher, J.E. et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96, 133–138 ( 1999).
van Beek, E. et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264, 108–111 ( 1999).
Plotkin, L.I. et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104, 1363 –1374 (1999).
Bauer, D.C. et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J. Bone Miner. Res. 14, S179 (abstract) (1999).
About this article
Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway
The FASEB Journal (2019)
Maxillary sinus lift using osteoinductive simvastatin combined with β-TCP versus β-TCP – a comparative pilot study to evaluate simvastatin enhanced and accelerated bone formation
Acta Odontologica Scandinavica (2018)
Lipids in Health and Disease (2018)
Histopathologic evaluation of the effects of local simvastatin application and photobiomodulation by light-emitting diode on bone healing of rat calvarial defects
Biotechnology & Biotechnological Equipment (2018)
Journal of Cranio-Maxillofacial Surgery (2014)